July 25, 2013 / 11:21 AM / in 4 years

Biogen new MS drug sales shine in first quarter on market

July 25 (Reuters) - Biogen Idec Inc on Thursday reported sales of its new multiple sclerosis drug Tecfidera that blew away initial Wall Street estimates, confirming an extremely strong launch for a medicine expected to dominate the market for oral treatments.

In its first quarter on the market, Tecfidera had sales of $192 million, including inventory stocking. Biogen said about $110 million of the total represented underlying patient demand. Analysts looked for about $66 million for the quarter.

Tecfidera is widely considered to be Biogen’s most important future growth driver, with analysts targeting eventual peak sales in excess of $3 billion. (Reporting by Bill Berkrot; Editing by Jeffrey Benkoe)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below